Here are the DEF 14A proxy statements from 4D Molecular Therapeutics, Inc. (FDMT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow FDMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FDMT filings page.
4D Molecular Therapeutics is asking stockholders to vote at its all-virtual 2026 annual meeting on June 17, 2026. Investors will elect three Class III directors, ratify PricewaterhouseCoopers as auditor for 2026, and cast a non-binding advisory vote on executive pay. Holders of 52,274,735 common shares as of April 20, 2026 may vote, with additional context of 16,935,665 shares issuable upon exercise of pre-funded warrants. The company details board structure, committee memberships, director compensation, and 2025 pay for named executives, including President and CEO David Kirn, M.D.